세계의 In Vivo CRO 시장 - 규모, 점유율, 동향 분석 보고서 : 모델 유형별, 모달리티별, 적응증별, GLP 유형별, 지역별, 부문 예측(2025-2030년)

In Vivo CRO Market Growth & Trends:

The global in vivo CRO market size is estimated to reach USD 7.96 billion by 2030, expanding at a CAGR of 8.13% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the pharmaceutical market in emerging countries, along with strong demand for numerous in vivo cell therapies, rapid advancements in material sciences, and complexities of drug-device combinations, has led to the demand for services in the region. Additionally, rising in vivo preclinical and clinical research, regulatory approval, expanding services by market players, and the burden of different diseases contribute to market earnings. Also, increasing outsourcing of preclinical and clinical services across developing economies at a lower cost is one of the major factors supporting the growth of in vivo CRO market.

Likewise, the increase in offshoring drugs to emerging economies has created immense demand for the market. Budget scrutiny in developed countries, pricing pressure, and changes in reimbursement schemes are some of the major factors anticipated to increase the adoption of cost-containment measures by drug sponsors in emerging countries such as India and China. Outsourcing development services such as preclinical in vivo services to contract service providers in emerging countries is expected to boost the demand for quality assurance & regulatory affairs services, thereby contributing to the rising demand for in vivo outsourced services. Stringent processes for FDA approval and regulatory changes in the EU region are expected to make the approval process in Europe complex. They are some of the major factors contributing to the offshoring of drug companies to emerging countries.

The COVID-19 pandemic has initially negatively impacted the clinical trials industry and the in vivo CRO market was no different! The shift in the focus of the biopharmaceutical industry on developing vaccines & therapies in response to COVID-19 has resulted in the unintended consequences of potentially disrupting clinical trials for other diseases. One of the key issues faced by companies operating in the cell and gene therapy industry is the untimely delivery of therapies to patients at required clinical sites. In addition, the administration of cell-based therapeutics poses several post-pandemic challenges. Hospitals have shown hesitation in offering cell therapy services owing to concerns over transmission of SARS-CoV-2, especially to vulnerable individuals. Patients have not been able to visit cell therapy centers either owing to the lockdowns or travel bans.

Furthermore, the key participants are engaged in strategies such as mergers & acquisitions, partnerships, agreements, collaborations, and service launches, among others, to expand their global footprints and service/product portfolio. For instance, in April 2023, PsychoGenics, Inc. announced the launch of eCube, a pharmaco-electroencephalography platform, to enhance phenotypic drug discovery. Similarly, in February 2023, Biocytogen recently introduced "the Nano 100 Project" to develop over 100 fully human nanobody drugs that target specific targets. This endeavor involves combining Biocytogen's proprietary RenNano, a mouse model capable of producing fully human nanobodies, with their advanced in vitro and in vivo antibody screening platforms. By leveraging these integrated technologies, Biocytogen is poised to facilitate the extensive development of fully human nanobody drugs.

In Vivo CRO Market Report Highlights:

• The rodent-based segment held the largest revenue share of 81.95% owing to constant model demand as they are genetically similar to humans. Besides, their small size, short life cycle, ease of maintenance, and availability of genetic resources, make them the most prevalent species in in-vivo CRO research
• The small molecule segment dominated the in vivo CRO market. The growth is attributed to the demand for small molecules in the development of drug candidates. In addition, the strong therapeutic effect of small molecules in a small dose is the key factor aiding segment growth
• The oncology segment dominated the global in vivo CRO market and accounted for a revenue share of 29.02% in 2024, the key factors contributing to the growth include the growing burden of cancer, surging demand for new gene therapy, and preclinical studies for cancer immunotherapy. According to the American Society of Gene Cell Therapy, around 97% of CAR T-cell therapies are developed for cancer indications
• The CNS conditions segment is anticipated to register the fastest growth, owing to the effectiveness of different model-based investigational compounds targeting brain diseases is expected to drive segment growth
• The GLP toxicology segment dominated the market with the largest revenue share in 2024 owing to the increasing number of standardized studies conducted according to specific guidelines
• North America held the largest revenue share of 50.0% in in-vivo CRO market in 2024. The growth in the region can be attributed to the presence of well-established market players, the increasing burden of different diseases, growing demand for CROs in the region. Other factors contributing to the growth are increased research and development activities, preclinical studies, and innovations of market players.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Modality
  • 1.2.2. Model Type
  • 1.2.3. Indication
  • 1.2.4. GLP Type
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. In Vivo CRO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Changing regulatory landscape
    • 3.2.1.2. Increase in offshoring medical device manufacturing to emerging countries
    • 3.2.1.3. Rising demand for advanced products
    • 3.2.1.4. Implementation of international standards by contract manufacturers
    • 3.2.1.5. Rising price competition and requirement to reduce cost
    • 3.2.1.6. Increasing complexity concerning product design and engineering
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Compliance Issues While Outsourcing
    • 3.2.2.2. Changing Scenarios in Developing Countries
    • 3.2.2.3. Regulatory And Legal Compliance
    • 3.2.2.4. Contractual Obligation
• 3.3. In Vivo CRO Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. In Vivo CRO Market: Modality Estimates & Trend Analysis

• 4.1. In Vivo CRO Market, By Modality: Segment Dashboard
• 4.2. In Vivo CRO Market, By Modality: Movement Analysis
• 4.3. In Vivo CRO Market Estimates & Forecasts, By Modality, 2018 - 2030
• 4.4. Small Molecule
  • 4.4.1. Small Molecule Market, 2018 to 2030 (USD Million)
• 4.5. Large Molecule
  • 4.5.1. Large Molecule Market, 2018 to 2030 (USD Million)
  • 4.5.2. Cell & Gene Therapy
    • 4.5.2.1. Cell & Gene Therapy Market, 2018 to 2030 (USD Million)
    • 4.5.2.2. CAR T-cell therapies
      • 4.5.2.2.1. CAR T-Cell Therapies Market, 2018 to 2030 (USD Million)
    • 4.5.2.3. CAR-NK cell therapy
      • 4.5.2.3.1. CAR-NK Cell Therapy Market, 2018 to 2030 (USD Million)
    • 4.5.2.4. TCR-T cell therapy
      • 4.5.2.4.1. TCR-T Cell Therapy Market, 2018 to 2030 (USD Million)
    • 4.5.2.5. Other Cell & Gene Therapy
      • 4.5.2.5.1. Other Cell & Gene Therapy Market, 2018 to 2030 (USD Million)
  • 4.5.3. RNA Therapy
    • 4.5.3.1. RNA Therapy Market, 2018 to 2030 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Others Market, 2018 to 2030 (USD Million)

Chapter 5. In Vivo CRO Market: Model Type Estimates & Trend Analysis

• 5.1. In Vivo CRO Market, By Model Type: Segment Dashboard
• 5.2. In Vivo CRO Market, By Model Type: Movement Analysis
• 5.3. In Vivo CRO Market Estimates & Forecasts, By Model Type, 2018 - 2030
• 5.4. Rodent based
  • 5.4.1. Rodent based Market, 2018 to 2030 (USD Million)
  • 5.4.2. Rat Models
    • 5.4.2.1. Rat Models Market, 2018 to 2030 (USD Million)
  • 5.4.3. Mice Models
    • 5.4.3.1. Mice Models Market, 2018 to 2030 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Others Market, 2018 to 2030 (USD Million)
• 5.5. Non-Rodent based
  • 5.5.1. Non-Rodent based Market, 2018 to 2030 (USD Million)

Chapter 6. In Vivo CRO Market: Indication Estimates & Trend Analysis

• 6.1. In Vivo CRO Market, By Indication: Segment Dashboard
• 6.2. In Vivo CRO Market, By Indication: Movement Analysis
• 6.3. In Vivo CRO Market Estimates & Forecasts, By Indication, 2018 - 2030
• 6.4. Autoimmune/inflammation conditions
  • 6.4.1. Autoimmune/inflammation conditions Market, 2018 to 2030 (USD Million)
  • 6.4.2. Rheumatoid Arthritis
    • 6.4.2.1. Rheumatoid Arthritis Market, 2018 to 2030 (USD Million)
  • 6.4.3. Multiple Sclerosis
    • 6.4.3.1. Multiple Sclerosis Market, 2018 to 2030 (USD Million)
  • 6.4.4. Osteoarthritis
    • 6.4.4.1. Osteoarthritis Market, 2018 to 2030 (USD Million)
  • 6.4.5. Irritable Bowel Syndrome
    • 6.4.5.1. Irritable Bowel Syndrome Market, 2018 to 2030 (USD Million)
  • 6.4.6. Others
    • 6.4.6.1. Others Market, 2018 to 2030 (USD Million)
• 6.5. Pain management
  • 6.5.1. Pain management Market, 2018 to 2030 (USD Million)
  • 6.5.2. Chronic pain
    • 6.5.2.1. Chronic pain Market, 2018 to 2030 (USD Million)
  • 6.5.3. Acute pain
    • 6.5.3.1. Acute pain Market, 2018 to 2030 (USD Million)
• 6.6. Oncology
  • 6.6.1. Oncology Market, 2018 to 2030 (USD Million)
  • 6.6.2. Blood cancer
    • 6.6.2.1. Blood Cancer Market, 2018 to 2030 (USD Million)
  • 6.6.3. Solid tumor
    • 6.6.3.1. Solid Tumor Market, 2018 to 2030 (USD Million)
    • 6.6.3.2. Syngeneic model
      • 6.6.3.2.1. Syngeneic Model Market, 2018 to 2030 (USD Million)
    • 6.6.3.3. Patient derived xenograft
      • 6.6.3.3.1. Patient Derived Xenograft Market, 2018 to 2030 (USD Million)
    • 6.6.3.4. Xenograft
      • 6.6.3.4.1. Xenograft Market, 2018 to 2030 (USD Million)
  • 6.6.4. Others
    • 6.6.4.1. Others Market, 2018 to 2030 (USD Million)
• 6.7. CNS Conditions
  • 6.7.1. CNS Conditions Market, 2018 to 2030 (USD Million)
  • 6.7.2. Epilepsy
    • 6.7.2.1. Epilepsy Market, 2018 to 2030 (USD Million)
  • 6.7.3. Parkinson's disease
    • 6.7.3.1. Parkinson's Disease Market, 2018 to 2030 (USD Million)
  • 6.7.4. Huntington's disease
    • 6.7.4.1. Huntington's Disease Market, 2018 to 2030 (USD Million)
  • 6.7.5. Stroke
    • 6.7.5.1. Stroke Market, 2018 to 2030 (USD Million)
  • 6.7.6. Muscular Dystrophy
    • 6.7.6.1. Muscular Dystrophy Market, 2018 to 2030 (USD Million)
  • 6.7.7. Alzheimer's Disease
    • 6.7.7.1. Alzheimer's Disease Market, 2018 to 2030 (USD Million)
  • 6.7.8. Traumatic brain injury
    • 6.7.8.1. Traumatic Brain Injury Market, 2018 to 2030 (USD Million)
  • 6.7.9. Amyotrophic lateral sclerosis (ALS)
    • 6.7.9.1. Amyotrophic Lateral Sclerosis (ALS) Market, 2018 to 2030 (USD Million)
  • 6.7.10. Spinal Muscular Atrophy
    • 6.7.10.1. Spinal Muscular Atrophy Market, 2018 to 2030 (USD Million)
  • 6.7.11. Muscle regeneration
    • 6.7.11.1. Muscle Regeneration Market, 2018 to 2030 (USD Million)
  • 6.7.12. Other Neurodevelopment Disorders
    • 6.7.12.1. Other Neurodevelopment Disorders Market, 2018 to 2030 (USD Million)
• 6.8. Diabetes
  • 6.8.1. Diabetes Market, 2018 to 2030 (USD Million)
• 6.9. Obesity
  • 6.9.1. Obesity Market, 2018 to 2030 (USD Million)
• 6.10. Others
  • 6.10.1. Others Market, 2018 to 2030 (USD Million)

Chapter 7. In Vivo CRO Market: GLP Type Estimates & Trend Analysis

• 7.1. In Vivo CRO Market, By GLP Type: Segment Dashboard
• 7.2. In Vivo CRO Market, By GLP Type: Movement Analysis
• 7.3. In Vivo CRO Market Estimates & Forecasts, By GLP Type, 2018 - 2030
• 7.4. Non GLP
  • 7.4.1. Non GLP Market, 2018 to 2030 (USD Million)
• 7.5. GLP Toxicology
  • 7.5.1. GLP Toxicology based Market, 2018 to 2030 (USD Million)

Chapter 8. In Vivo CRO Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. North America
  • 8.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. U.S
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. Australia
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Company Market Share Analysis, 2023/24
• 9.3. Company Profiles
  • 9.3.1. IQVIA Inc
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Crown Bioscience
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Taconic Biosciences, Inc.
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. PsychoGenics Inc.
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Evotec
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Janvier Labs
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Biocytogen
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. GemPharmatech
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Charles River Laboratories
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Icon Plc
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Labcorp Drug Development
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. Parexel International Corporation
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Service Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. SMO Clinical Research (I) Pvt Ltd
    • 9.3.13.1. Company Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Service Benchmarking
    • 9.3.13.4. Strategic Initiatives

Chapter 10 Key Recommendations